Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologic toxicities of grade > or = 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.
Hantel
A
A
Loyola University Stritch School of Medicine, Maywood, IL.
Tangen
C M
CM
Macdonald
J S
JS
Richman
S P
SP
Pugh
R P
RP
Pollock
T
T
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016597:Trimetrexate / Q000009:adverse effects / Q000627:therapeutic use*
D016597:Trimetrexate